| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.1093/CVR/CVP165 |
| P698 | PubMed publication ID | 19502281 |
| P50 | author | Valentín Fuster Carulla | Q977751 |
| Philippe Gabriel Steg | Q16027739 | ||
| Elisabetta Cerbai | Q43141378 | ||
| Gerard Pasterkamp | Q57298458 | ||
| P2093 | author name string | M. Vidal | |
| G. Hasenfuss | |||
| M. Wehling | |||
| S. D. Kristensen | |||
| H. Schunkert | |||
| F. Rademakers | |||
| D. Garcia-Dorado | |||
| F. Fernandez-Aviles | |||
| B. Casadei | |||
| K. R. Sipido | |||
| A. Tedgui | |||
| M. Hallen | |||
| V. Dambrauskaite | |||
| W. Eisert | |||
| P2860 | cites work | The Role of Molecular Imaging in Drug Discovery and Development | Q22121985 |
| Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: | Q22242896 | ||
| Regenerating the heart | Q22251075 | ||
| Epidemiology of sudden cardiac death: clinical and research implications | Q24650947 | ||
| Genomewide association analysis of coronary artery disease | Q24658344 | ||
| Induced pluripotent stem cell lines derived from human somatic cells | Q27860597 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial | Q28181984 | ||
| Reprogramming of human somatic cells to pluripotency with defined factors | Q28262710 | ||
| Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern | Q28291903 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Effect of in utero and early-life conditions on adult health and disease | Q29615797 | ||
| MicroRNA-133 controls cardiac hypertrophy | Q29616572 | ||
| Ultrasound molecular imaging with targeted microbubble contrast agents | Q30445036 | ||
| Mechanisms of sudden cardiac death. | Q33930892 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| Report of the National Heart, Lung, and Blood Institute working group on outcomes research in cardiovascular disease | Q34426512 | ||
| Cytokines in atherosclerosis: pathogenic and regulatory pathways | Q34511711 | ||
| Upsurge in T-wave alternans and nonalternating repolarization instability precedes spontaneous initiation of ventricular tachyarrhythmias in humans. | Q34539968 | ||
| Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications | Q34576422 | ||
| Dofetilide: a new class III antiarrhythmic agent | Q34594440 | ||
| New therapeutic options in congestive heart failure: Part I. | Q34617577 | ||
| Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction | Q34631845 | ||
| Myocardial reperfusion injury. | Q34687124 | ||
| Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis | Q34761842 | ||
| Cardiac plasticity | Q34764732 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Genetics of cardiac arrhythmias and sudden cardiac death | Q35807700 | ||
| Lessons from the management of chronic heart failure | Q35808265 | ||
| Perinatal arrhythmias: diagnosis and management | Q35846747 | ||
| Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? | Q35868133 | ||
| Multi-modality imaging to assess left atrial size, anatomy and function | Q36057119 | ||
| Temporal trends in the utilization of diagnostic testing and treatments for cardiovascular disease in the United States, 1993-2001. | Q36238016 | ||
| Realizing the clinical potential of ischemic preconditioning and postconditioning. | Q36301135 | ||
| Postconditioning: reduction of reperfusion-induced injury | Q36424366 | ||
| Mitochondrial permeability transition pore and postconditioning | Q36437912 | ||
| The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia-reperfusion. | Q36458799 | ||
| Regeneration gaps: observations on stem cells and cardiac repair | Q36472071 | ||
| Atherosclerosis neovascularization and imaging | Q36570094 | ||
| Cardiovascular proteomics: tools to develop novel biomarkers and potential applications | Q36644478 | ||
| Innovative approaches to anti-arrhythmic drug therapy. | Q36670460 | ||
| Drug discovery for heart failure: a new era or the end of the pipeline? | Q36724656 | ||
| Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). | Q36727629 | ||
| Anticoagulants in heart disease: current status and perspectives | Q36787643 | ||
| T(H)1 cells control themselves by producing interleukin-10. | Q36831662 | ||
| Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis | Q36942534 | ||
| Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs | Q36944481 | ||
| Low priority of cardiovascular and chronic diseases on the global health agenda: a cause for concern | Q36983573 | ||
| Nuclear imaging in cardiac resynchronization therapy | Q37023108 | ||
| Update on atrial fibrillation: part I. | Q37079006 | ||
| Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria | Q37124007 | ||
| Update on atrial fibrillation: part II. | Q37126166 | ||
| Spotlight on HDL-raising therapies: insights from the torcetrapib trials | Q37145837 | ||
| Implantable device therapy | Q37161649 | ||
| Stem-cell-based therapy and lessons from the heart | Q37164041 | ||
| Form to function: current and future roles for atherosclerosis imaging in drug development | Q37165155 | ||
| MicroRNAs: novel regulators in cardiac development and disease | Q37176880 | ||
| Aging and disease as modifiers of efficacy of cell therapy | Q37183949 | ||
| Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization | Q37209749 | ||
| Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease | Q37211205 | ||
| New susceptibility locus for coronary artery disease on chromosome 3q22.3. | Q37225243 | ||
| Cardiac magnetic resonance assessment of mechanical dyssynchrony | Q37231551 | ||
| Arrhythmia mechanisms in the failing heart | Q37236524 | ||
| New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | Q37268006 | ||
| A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. | Q37274482 | ||
| A systematic review of exercise interventions in patients with heart failure | Q37284275 | ||
| Targeting calcium handling in arrhythmias | Q37290746 | ||
| Model systems for the discovery and development of antiarrhythmic drugs. | Q37336148 | ||
| The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction | Q37353115 | ||
| Academic careers in cardiovascular medicine | Q37388952 | ||
| Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. | Q38963267 | ||
| Notes from the director of the National Heart, Lung, and Blood Institute: shaping the future of research: the NHLBI strategic plan | Q40152578 | ||
| Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. | Q40450238 | ||
| Meta-analysis and profiling of cardiac expression modules. | Q41956816 | ||
| Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease | Q43617306 | ||
| A polypill for secondary prevention: time to move from intellectual debate to action | Q44197277 | ||
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 | ||
| Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. | Q46028444 | ||
| Effect of cyclosporine on reperfusion injury in acute myocardial infarction | Q46453592 | ||
| A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). | Q46528602 | ||
| Postconditioning the human heart | Q46722557 | ||
| Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice | Q46859383 | ||
| Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials | Q46928598 | ||
| The making of a physician-scientist--the process has a pattern: lessons from the lives of Nobel laureates in medicine and physiology | Q48332670 | ||
| Shattuck lecture--clinical research to clinical practice--lost in translation? | Q48569309 | ||
| Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. | Q50693621 | ||
| Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis | Q53591922 | ||
| Expanding the cardiovascular mandate: from treatment to the protection of health | Q56986736 | ||
| Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 | Q57243464 | ||
| P433 | issue | 3 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 425-435 | |
| P577 | publication date | 2009-06-05 | |
| P1433 | published in | Cardiovascular Research | Q4642329 |
| P1476 | title | Identifying needs and opportunities for advancing translational research in cardiovascular disease | |
| P478 | volume | 83 |
| Q35274466 | Autophagy is a regulator of TGF-β1-induced fibrogenesis in primary human atrial myofibroblasts |
| Q38541945 | Barriers to cardiovascular device innovation in Europe |
| Q26797153 | Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria |
| Q64106289 | Cardiovascular events, diabetes and guidelines: the virtue of simplicity |
| Q54687542 | Championing cardiovascular health innovation in Europe. |
| Q49602782 | Current matters of the heart |
| Q37912523 | Drug development in the light of translational science: shine or shade? |
| Q34788746 | Epigenetics and cardiovascular disease |
| Q38528288 | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| Q36974291 | Lack of Reduction of Left Ventricular Mass in Treated Hypertension: The Strong Heart Study |
| Q54621218 | Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. |
| Q34544884 | Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of ⁹⁹(m)Tc-labeled cells activity |
| Q84758236 | Scientific societies and biomedical research |
| Q34028768 | The Trial Using Motivational Interviewing and Positive Affect and Self-Affirmation in African-Americans with Hypertension (TRIUMPH): From theory to clinical trial implementation |
Search more.